Successful treatment of checkpoint inhibitor-associated bullous pemphigoid with dupilumab in a patient with angiosarcoma

被引：3
|
作者：
Hansen, Inga [1 ,2 ]
Gebhardt, Christoffer [1 ]
Booken, Nina [1 ]
Schneider, Stefan W. [1 ]
机构：
[1] Univ klinikum Hamburg Eppendorf, Klin Poliklin Dermatol & Venerol, Hamburg, Germany
[2] Univ klinikum Hamburg Eppendorf, Klin Dermatol & Venerol, Martinistr 52, Hamburg, 20246, Germany
来源：
JOURNAL DER DEUTSCHEN DERMATOLOGISCHEN GESELLSCHAFT | 2024年 / 22卷 / 04期
关键词：
D O I：
10.1111/ddg.15340
中图分类号：
R75 [皮肤病学与性病学];
学科分类号：
100206 ;
摘要：
引用
收藏
页码：587 / 589
页数：3
相关论文
共 50 条
  • [41] A successful treatment with ustekinumab in a case of relapsing bullous pemphigoid associated with psoriasis
    Loget, J.
    Plee, J.
    Antonicelli, F.
    Bernard, P.
    JOURNAL OF THE EUROPEAN ACADEMY OF DERMATOLOGY AND VENEREOLOGY, 2017, 31 (05) : e228 - e230
  • [42] Immune checkpoint inhibitor-associated hypercalcaemia
    Izzedine, Hassan
    Chazal, Thibaud
    Wanchoo, Rimda
    Jhaveri, Kenar D.
    NEPHROLOGY DIALYSIS TRANSPLANTATION, 2022, 37 (09) : 1598 - 1608
  • [43] Immune Checkpoint Inhibitor-Associated Myocarditis
    Ganatra, Sarju
    Neilan, Tomas G.
    ONCOLOGIST, 2018, 23 (08): : 879 - 886
  • [44] Checkpoint inhibitor-associated immune arthritis
    Arnaud, Laurent
    Lebrun-Vignes, Benedicte
    Salem, Joe-Elie
    ANNALS OF THE RHEUMATIC DISEASES, 2019, 78 (07)
  • [45] IMMUNE CHECKPOINT INHIBITOR-ASSOCIATED MYOPATHY
    Pavia Pascual, M.
    De La Torre Rubio, N.
    Machattou, M.
    Navarro Palomo, P.
    Navarro Joven, C.
    Alonso de Francisco, M.
    Barbadillo Mateos, C.
    Merino Argumanez, C.
    Godoy, H.
    Fernandez Castro, M.
    Garcia-Magallon, B.
    Sanz, J.
    De Villa, L. F.
    Andreu Sanchez, J. L.
    Campos Esteban, J.
    ANNALS OF THE RHEUMATIC DISEASES, 2023, 82 : 1647 - 1648
  • [46] Immune Checkpoint Inhibitor-Associated Nephrotoxicity
    Mamlouk, Omar R.
    Danesh, Farhad
    NEPHRON, 2023, : 11 - 15
  • [47] Immune checkpoint inhibitor-induced bullous pemphigoid is characterized by interleukin (IL)-4 and IL-13 expression and responds to dupilumab treatment
    Shipman, William D.
    Singh, Katelyn
    Cohen, Jeffrey M.
    Leventhal, Jonathan
    Damsky, William
    Tomayko, Mary M.
    BRITISH JOURNAL OF DERMATOLOGY, 2023, 189 (03) : 339 - 341
  • [48] Clinical diagnosis and treatment of immune checkpoint inhibitor-associated pneumonitis
    Wang, Hanping
    Guo, Xiaoxiao
    Zhou, Jiaxin
    Li, Yue
    Duan, Lian
    Si, Xiaoyan
    Zhang, Li
    Liu, Xiaowei
    Wang, Mengzhao
    Shi, Juhong
    Zhang, Li
    THORACIC CANCER, 2020, 11 (01) : 191 - 197
  • [49] Immune Checkpoint Inhibitor-Associated Pericarditis
    Altan, Mehmet
    Toki, Maria I.
    Gettinger, Scott N.
    Carvajal-Hausdorf, Daniel E.
    Zugazagoitia, Jon
    Sinard, John H.
    Herbst, Roy S.
    Rimm, David L.
    JOURNAL OF THORACIC ONCOLOGY, 2019, 14 (06) : 1102 - 1108
  • [50] Exacerbation of clinical manifestations of bullous pemphigoid after treatment with dupilumab
    Mariotti, Elena Biancamaria
    Corra, Alberto
    Aimo, Cristina
    di Calabria, Valentina Ruffo
    Quintarelli, Lavinia
    Verdelli, Alice
    Caproni, Marzia
    CLINICAL AND EXPERIMENTAL DERMATOLOGY, 2024, 49 (04) : 399 - 400
12345